Sector News

France’s Delpharm in talks to buy 5 Famar sites for $274M

October 7, 2019
Life sciences

French CDMO Delpharm, which already has a dozen sites across Europe, is planning a big expansion with a deal to pick up five more, including one in North America, along with 1,300 employees in a deal worth more than $250 million.

Delpharm said in an emailed release today that it is in exclusive negotiations with Greece-based Famar to buy French sites in Orléans (Loiret), Aigle (Orne) and St-Rémy-sur-Avre (Eure-et-Loire), along with Famar’s site in Bladel in the Netherlands and its Pointe-Claire site in Quebec, Canada.

The deal, which covers nearly half of the financially-struggling Famar’s network of 11 sites, represents an investment of €250 million ($274 million), Delpharm said. The CDMO’s expect to close the deal in November.

“The Board of Directors has agreed that the offer proposed by Delpharm is in the best interest of the five sites and their employees,” Delpharm President Patrick Puy, said in a statement. “The completion of this transaction will allow these sites to enter into a new phase of sustainable and promising development.”

Athens-based Famar had been aggressively building its network several years ago. In 2016 it acquired an FDA-approved site in Leganes, Spain, from Roche. The following year, Delpharm also bought a site from Roche, this one in Segrate, Italy.

But Famar’s parent, the Marinopoulos Group, ran into financial problems several years ago. At the end of last year, Reuters reported that Famar completed a €174 million debt restructuring and got an infusion of cash from private equity-backed Pillarstone.

By Eric Palmer

Source: Fierce Pharma

Related News

July 9, 2020

Novartis partners with Civica Rx to ease hospital shortages for 6 high-demand generic injectables

Life sciences

The COVID-19 pandemic and its drain on key drugs used in acute care has put an enormous strain on hospitals in desperate need of medicines for their patients. In a […]

July 9, 2020

New clinical trial platform launched to accelerate COVID-19 treatments

Life sciences

The University of Liverpool, Liverpool School of Tropical Medicine and Southampton Clinical Trials Unit have launched an innovative COVID-19 drug testing platform, AGILE, in the hope of accelerating the development […]

July 7, 2020

Novartis banks EC approval for Enerzair Breezhaler

Life sciences

The European Commission (EC) has approved Novartis’ Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma. More specifically, the drug has been cleared as a maintenance treatment […]